Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Discovery of ancient pleasure boat reveals Egypt's maritime history08.12.2025 - 26 Exceptionally Appraised Summer Travel Objections06.06.2024
- 3Black Friday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows25.11.2025
- 4Sa'ar warns German delegation: 'A Palestinian state would be a Hamas terror state'16.11.2025
- 5Putin says Russian forces will seize capital of Zaporizhzhya29.12.2025
- 'Pluribus' release date: Everything you need to know about the new series from 'Better Call Saul's' co-creator
- How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- Figure out How to Function Successfully with Your Auto Collision Legal advisor for the Best Result
- Reporter's Notebook: The Post embeds with foreign armies visiting the IDF
- Shredded cheese recall: Multiple brands sold at Aldi, Target and Walmart affected over potential metal fragment contamination
- Chemical leak in Oklahoma forces evacuations and leaves many ill
- Instructions to Pick the Right Toothpaste for Your Dental Requirements
- Most loved Occasion Dish: What Makes Your Merry Table?
- Mars orbiter sees 'butterfly' crater spread its wings on the Red Planet
